Brendan T Griffin

List of Publications by Year
in descending order

90 papers	3,499 citations	126907 33 h-index	149698 56 g-index
91 all docs	91 docs citations	91 times ranked	4809 citing authors

#	Article	IF	Citations
1	Machine learning methods for prediction of food effects on bioavailability: A comparison of support vector machines and artificial neural networks. European Journal of Pharmaceutical Sciences, 2022, 168, 106018.	4.0	17
2	Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review. European Journal of Pharmaceutical Sciences, 2022, 170, 106098.	4.0	29
3	Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 5-26.	3.3	4
4	Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series. Pharmaceutics, 2022, 14, 1010.	4.5	7
5	Characterization of gastrointestinal transit and luminal conditions in pigs using a telemetric motility capsule. European Journal of Pharmaceutical Sciences, 2021, 156, 105627.	4.0	31
6	Applying Computational Predictions of Biorelevant Solubility Ratio Upon Self-Emulsifying Lipid-Based Formulations Dispersion to Predict Dose Number. Journal of Pharmaceutical Sciences, 2021, 110, 164-175.	3.3	5
7	Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration. Journal of Pharmacy and Pharmacology, 2021, 73, 437-446.	2.4	8
8	The gut microbiome influences the bioavailability of olanzapine in rats. EBioMedicine, 2021, 66, 103307.	6.1	38
9	Exploring precipitation inhibitors to improve in vivo absorption of cinnarizine from supersaturated lipid-based drug delivery systems. European Journal of Pharmaceutical Sciences, 2021, 159, 105691.	4.0	16
10	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Advanced Drug Delivery Reviews, 2021, 171, 289-331.	13.7	84
11	In Silico, In Vitro, and In Vivo Evaluation of Precipitation Inhibitors in Supersaturated Lipid-Based Formulations of Venetoclax. Molecular Pharmaceutics, 2021, 18, 2174-2188.	4.6	11
12	Synthesis and In Vivo Evaluation of Insulin-Loaded Whey Beads as an Oral Peptide Delivery System. Pharmaceutics, 2021, 13, 656.	4.5	4
13	Rational Selection of Bio-Enabling Oral Drug Formulations â€“ A PEARRL Commentary. Journal of Pharmaceutical Sciences, 2021, 110, 1921-1930.	3.3	12
14	Exploring porcine gastric and intestinal fluids using microscopic and solubility estimates: Impact of placebo self-emulsifying drug delivery system administration to inform bio-predictive in vitro tools. European Journal of Pharmaceutical Sciences, 2021, 161, 105778.	4.0	2
15	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. European Journal of Pharmaceutical Sciences, 2021, 162, 105812.	4.0	137
16	Combining species specific in vitro & in silico models to predict in vivo food effect in a preclinical stage â€“ case study of Venetoclax. European Journal of Pharmaceutical Sciences, 2021, 162, 105840.	4.0	8
17	Artificial Neural Networks to Predict the Apparent Degree of Supersaturation in Supersaturated Lipid-Based Formulations: A Pilot Study. Pharmaceutics, 2021, 13, 1398.	4.5	8
18	Lipophilic salts and lipid-based formulations for bridging the food effect gap of venetoclax. Journal of Pharmaceutical Sciences, 2021, , .	3.3	3

#	Article	IF	Citations
19	A Retrospective Biopharmaceutical Analysis of >800 Approved Oral Drug Products: Are Drug Properties of Solid Dispersions and Lipid-Based Formulations Distinctive?. Journal of Pharmaceutical Sciences, 2020, 109, 3248-3261.	3.3	19
20	Development and evaluation of a biorelevant medium simulating porcine gastrointestinal fluids. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 116-126.	4.3	14
21	Exploring the Impact of Surfactant Type and Digestion: Highly Digestible Surfactants Improve Oral Bioavailability of Nilotinib. Molecular Pharmaceutics, 2020, 17, 3202-3213.	4.6	24
22	Novel Biphasic Lipolysis Method To Predict in Vivo Performance of Lipid-Based Formulations. Molecular Pharmaceutics, 2020, 17, 3342-3352.	4.6	18
23	A phase 1, single-blind, placebo-controlled, 3-arm cross-over trial assessing the appetite enhancing effects of potentially ghrelinergic dairy-derived peptides. Proceedings of the Nutrition Society, 2020, 79, .	1.0	0
24	Toward simplified oral lipid-based drug delivery using mono-/di-glycerides as single component excipients. Drug Development and Industrial Pharmacy, 2020, 46, 2051-2060.	2.0	6
25	Chase Dosing of Lipid Formulations to Enhance Oral Bioavailability of Nilotinib in Rats. Pharmaceutical Research, 2020, 37, 124.	3.5	8
26	Impact of host and environmental factors on Î²-glucuronidase enzymatic activity: implications for gastrointestinal serotonin. American Journal of Physiology - Renal Physiology, 2020, 318, G816-G826.	3.4	25
27	Supersaturated Lipid-Based Formulations to Enhance the Oral Bioavailability of Venetoclax. Pharmaceutics, 2020, 12, 564.	4.5	19
28	Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across Permeapadâ“‡ membrane and in vivo absorption. European Journal of Pharmaceutical Sciences, 2020, 152, 105452.	4.0	17
29	Behavioural characterization of ghrelin ligands, anamorelin and HM01: Appetite and reward-motivated effects in rodents. Neuropharmacology, 2020, 168, 108011.	4.1	6
30	Supersaturated lipid-based drug delivery systems â€“ exploring impact of lipid composition type and drug properties on supersaturability and physical stability. Drug Development and Industrial Pharmacy, 2020, 46, 356-364.	2.0	14
31	Gut microbiome-mediated modulation of hepatic cytochrome P450 and P-glycoprotein: impact of butyrate and fructo-oligosaccharide-inulin. Journal of Pharmacy and Pharmacology, 2020, 72, 1072-1081.	2.4	13
32	Perspectives of pharmacists on facilitating experiential learning placements for pharmacy students in non-patient facing settings. Currents in Pharmacy Teaching and Learning, 2020, 12, 901-909.	1.0	2
33	Food for thought: formulating away the food effect â€“ a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 510-535.	2.4	75
34	Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches â€“ a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 464-482.	2.4	76
35	Application of the solubility parameter concept to assist with oral delivery of poorly water-soluble drugs â€“ a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 441-463.	2.4	39
36	Toward the establishment of a standardized pre-clinical porcine model to predict food effects â€“ Case studies on fenofibrate and paracetamol. International Journal of Pharmaceutics: X, 2019, 1, 100017.	1.6	3

#	Article	IF	Citations
37	Gut Reactions: Breaking Down Xenobioticâ€“Microbiome Interactions. Pharmacological Reviews, 2019, 71, 198-224.	16.0	211
38	The PEARRL reviews â€“ innovative drug development strategies tailored to facilitate earlier access to new oral medicines. Journal of Pharmacy and Pharmacology, 2019, 71, 439-440.	2.4	3
39	New Insights into Using Lipid Based Suspensions for â€˜Brick Dustâ€™ Molecules: Case Study of Nilotinib. Pharmaceutical Research, 2019, 36, 56.	3.5	23
40	Regulation of biosimilar medicines and current perspectives on interchangeability and policy. European Journal of Clinical Pharmacology, 2019, 75, 1-11.	1.9	54
41	The pig as a preclinical model for predicting oral bioavailability and in vivo performance of pharmaceutical oral dosage forms: a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 581-602.	2.4	53
42	Microbiome-mediated bile acid modification: Role in intestinal drug absorption and metabolism. Pharmacological Research, 2018, 133, 170-186.	7.1	66
43	Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS): A rapid test for enteric coating thickness and integrity of controlled release pellet formulations. International Journal of Pharmaceutics, 2018, 544, 31-38.	5.2	6
44	Application of a physiologicallyâ€based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate. Biopharmaceutics and Drug Disposition, 2018, 39, 125-134.	1.9	9
45	Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland. BioDrugs, 2018, 32, 267-280.	4.6	26
46	Exploring gastric emptying rate in minipigs: Effect of food type and pre-dosing of metoclopramide. European Journal of Pharmaceutical Sciences, 2018, 118, 183-190.	4.0	14
47	Sustained-release multiparticulates for oral delivery of a novel peptidic ghrelin agonist: Formulation design and in vitro characterization. International Journal of Pharmaceutics, 2018, 536, 63-72.	5.2	14
48	A Dairy-Derived Ghrelinergic Hydrolysate Modulates Food Intake In Vivo. International Journal of Molecular Sciences, 2018, 19, 2780.	4.1	5
49	Drugâ€“gut microbiota interactions: implications for neuropharmacology. British Journal of Pharmacology, 2018, 175, 4415-4429.	5.4	93
50	In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation. Journal of Controlled Release, 2017, 250, 86-95.	9.9	27
51	Impact of Gut Microbiota-Mediated Bile Acid Metabolism on the Solubilization Capacity of Bile Salt Micelles and Drug Solubility. Molecular Pharmaceutics, 2017, 14, 1251-1263.	4.6	54
52	Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate. Journal of Pharmacy and Pharmacology, 2017, 69, 1284-1292.	2.4	14
53	Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland. Regulatory Toxicology and Pharmacology, 2017, 88, 252-261.	2.7	45
54	From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation. International Journal of Molecular Sciences, 2017, 18, 273.	4.1	112

#	Article	IF	Citations
55	Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 2341-2351.	3.3	48
56	Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. Clinical Nutrition ESPEN, 2016, 13, e39-e45.	1.2	81
57	Lipid-based nanocarriers for oral peptide delivery. Advanced Drug Delivery Reviews, 2016, 106, 337-354.	13.7	204
58	Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics. British Journal of Clinical Pharmacology, 2016, 81, 62-77.	2.4	7
59	Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs. Advanced Drug Delivery Reviews, 2016, 106, 367-380.	13.7	83
60	Pharmacotherapy for Neonatal Seizures: Current Knowledge and Future Perspectives. Drugs, 2016, 76, 647-661.	10.9	64
61	In vitro bidirectional permeability studies identify pharmacokinetic limitations of NKCC1 inhibitor bumetanide. European Journal of Pharmacology, 2016, 770, 117-125.	3.5	17
62	Enhanced colonic delivery of ciclosporin A self-emulsifying drug delivery system encapsulated in coated minispheres. Drug Development and Industrial Pharmacy, 2016, 42, 245-253.	2.0	25
63	Regulatory Science Ireland: bridging the information gap on biosimilar medicines. GaBI Journal, 2016, 5, 168-170.	0.3	0
64	The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome. Yale Journal of Biology and Medicine, 2016, 89, 375-382.	0.2	78
65	Chronic Pâ€glycoprotein inhibition increases the brain concentration of escitalopram: potential implications for treating depression. Pharmacology Research and Perspectives, 2015, 3, e00190.	2.4	5
66	Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 96, 207-216.	4.3	28
67	Exploring the Impact of Drug Properties on the Extent of Intestinal Lymphatic Transport - In Vitro and In Vivo Studies. Pharmaceutical Research, 2015, 32, 1817-1829.	3.5	28
68	The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat. Journal of Pharmacy and Pharmacology, 2015, 67, 501-510.	2.4	26
69	Impact of body composition parameters on clinical outcomes in patients with metastatic castration-resistant prostate cancer treated with docetaxel. Journal of Clinical Oncology, 2015, 33, e16121-e16121.	1.6	0
70	The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram. Behavioural Brain Research, 2014, 261, 17-25.	2.2	11
71	Silicon microfluidic flow focusing devices for the production of size-controlled PLGA based drug loaded microparticles. International Journal of Pharmaceutics, 2014, 467, 60-69.	5.2	39
72	Biopharmaceutical Modeling of Drug Supersaturation During Lipid-Based Formulation Digestion Considering an Absorption Sink. Pharmaceutical Research, 2014, 31, 3426-3444.	3.5	35

#	Article	IF	Citations
73	PEGylated cyclodextrins as novel siRNA nanosystems: Correlations between polyethylene glycol length and nanoparticle stability. International Journal of Pharmaceutics, 2014, 473, 105-112.	5.2	45
74	Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: Case studies with fenofibrate. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 427-437.	4.3	111
75	P-glycoprotein Inhibition Increases the Brain Distribution and Antidepressant-Like Activity of Escitalopram in Rodents. Neuropsychopharmacology, 2013, 38, 2209-2219.	5.4	47
76	A novel lipid-based solid dispersion for enhancing oral bioavailability of Lycopene â€“ In vivo evaluation using a pig model. International Journal of Pharmaceutics, 2013, 453, 307-314.	5.2	54
77	Human P-glycoprotein differentially affects antidepressant drug transport: relevance to bloodâ€“brain barrier permeability. International Journal of Neuropsychopharmacology, 2013, 16, 2259-2272.	2.1	37
78	Inhibition of Pâ€glycoprotein enhances transport of imipramine across the bloodâ€“brain barrier: microdialysis studies in conscious freely moving rats. British Journal of Pharmacology, 2012, 166, 1333-1343.	5.4	41
79	Interactions between antidepressants and Pâ€glycoprotein at the bloodâ€“brain barrier: clinical significance of in vitro and in vivo findings. British Journal of Pharmacology, 2012, 165, 289-312.	5.4	171
80	Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. Therapeutic Delivery, 2011, 2, 1633-1653.	2.2	27
81	Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins. Current Gene Therapy, 2010, 10, 34-45.	2.0	56
82	A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model. Journal of Pharmacy and Pharmacology, 2010, 58, 917-925.	2.4	57
83	Bioavailability of lycopene in the rat: the role of intestinal lymphatic transport. Journal of Pharmacy and Pharmacology, 2010, 62, 323-331.	2.4	41
84	Expression of two Listeria monocytogenes antigens (P60 and LLO) in Lactococcus lactis and examination for use as live vaccine vectors. Journal of Medical Microbiology, 2010, 59, 904-912.	1.8	23
85	<p class="p1"> Efficacy of aLactococcus lactisÎ”pyrGvaccine delivery platform expressing chromosomally integratedhlyfromListeria monocytogenes. Bioengineered Bugs, 2010, 1, 66-74.	1.7	27
86	An Examination of the Effect of Intestinal First Pass Extraction on Intestinal Lymphatic Transport of Saquinavir in the Rat. Pharmaceutical Research, 2008, 25, 1125-1133.	3.5	12
87	Biopharmaceutical challenges associated with drugs with low aqueous solubilityâ€”The potential impact of lipid-based formulations. Advanced Drug Delivery Reviews, 2008, 60, 617-624.	13.7	252
88	Nisin inducible production of listeriolysin O in Lactococcus lactis NZ9000. Microbial Cell Factories, 2008, 7, 24.	4.0	27
89	Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8+ T cells against Listeria monocytogenes in the murine infection model. Vaccine, 2008, 26, 5304-5314.	3.8	47
90	Models of the Small Intestine. , 2008, , 34-76.		14